Company intelligence / Profile preview

Alberville

Paris, France

Ownership: Private
Development stage: Other

Overview

Alberville is a biotechnology company focused on the development of novel therapeutic agents for the treatment of oncology and infectious diseases. The company leverages its expertise in medicinal chemistry and molecular biology to identify and optimize small molecule candidates that target critical pathways in disease progression. Alberville's research programs are currently in the pre-clinical stage, with a focus on establishing proof-of-concept and safety profiles for its lead compounds. The company aims to address significant unmet medical needs through the development of innovative and effective therapies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Alberville.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alberville.

Explore the full profile